Evidence map›Paper›PMID 23532923›Full record

ArticleHepatology (Baltimore, Md.)2013

Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection.

Shirin Ashraf, Katja Nitschke, Usama M Warshow, Collin R Brooks, Arthur Y Kim, Georg M Lauer, Theresa J Hydes, Matthew E Cramp, Graeme Alexander, Ann-Margaret Little and 3 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Hepatology (Baltimore, Md.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Genetic variation that determinesProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  3. Current Challenges in Vaccinology.Frontiers in immunology · 2020
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Shirin AshrafClinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK.
Katja Nitschke
Usama M Warshow
Collin R Brooks
Arthur Y Kim
Georg M Lauer
Theresa J Hydes
Matthew E Cramp
Graeme Alexander
Ann-Margaret Little
Robert Thimme
Christoph Neumann-Haefelin
Salim I Khakoo
University of Southampton · GBDerriford Hospital · GBUniversity Medical Center Freiburg · DEBridge Pharma (United States) · USImmungenetics (Germany) · DEInternational Society for Infectious Diseases · USMassachusetts General Hospital · USUniversity of Freiburg · DE

Funding

Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1M
The role of NK cells during acute HCV infection and antiviral therapyU19AI066345 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2005 to 2014
$8.5M
Discovery and Assessment of Genetic Determinants of HCV and HIV ControlR01DA033541 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, KIM, ARTHUR Y · 2011 to 2015
$3.4M
Medical Research Council G1001738NIAID NIH HHS U19 AI0663445NIAID NIH HHS U19 AI066345NIAID NIH HHS U19 AI082630NIDA NIH HHS R01 DA033541Wellcome Trust
6 · The paper itself

Abstract

unlabelledCD8+ T-cell responses to hepatitis C virus (HCV) are important in generating a successful immune response and spontaneously clearing infection. Human leukocyte antigen (HLA) class I presents viral peptides to CD8+ T cells to permit detection of infected cells, and tapasin is an important component of the peptide loading complex for HLA class I. We sought to determine if tapasin polymorphisms affected the outcome of HCV infection. Patients with resolved or chronic HCV infection were genotyped for the known G/C coding polymorphism in exon 4 of the tapasin gene. In a European, but not a US, Caucasian population, the tapasin G allele was significantly associated with the outcome of HCV infection, being found in 82.5% of resolvers versus 71.3% of persistently infected individuals (P = 0.02, odds ratio [OR] = 1.90 95% confidence interval [CI] = 1.11-3.23). This was more marked at the HLA-B locus at which heterozygosity of both tapasin and HLA-B was protective (P < 0.03). Individuals with an HLA-B allele with an aspartate at residue 114 and the tapasin G allele were more likely to spontaneously resolve HCV infection (P < 0.00003, OR = 3.2 95% CI = 1.6-6.6). Additionally, individuals with chronic HCV and the combination of an HLA-B allele with an aspartate at residue 114 and the tapasin G allele also had stronger CD8+ T-cell responses (P = 0.02, OR = 2.58, 95% CI-1.05-6.5).

conclusionTapasin alleles contribute to the outcome of HCV infection by synergizing with polymorphisms at HLA-B in a population-specific manner. This polymorphism may be relevant for peptide vaccination strategies against HCV infection.

Indexed as

HepacivirusAdultAllelesAntiviral AgentsCohort StudiesFemaleHepatitis CHLA AntigensHLA-B AntigensHumansLogistic ModelsMaleMembrane Transport ProteinsMiddle AgedPolymorphism, GeneticPrognosisAntiviral AgentsHLA AntigensHLA-B AntigensMembrane Transport Proteinstapasin

Identifiers

PMID23532923
PMCPMC3759612
OpenAlexW2114017479

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.